Two Doors Into the Growth Hormone Axis: GHRH vs Ghrelin

There are two completely different doors into the growth hormone axis, and most of the people selling you peptides do not know there are two.

Every GH compound in circulation works through one of two receptors sitting on the same pituitary cell. Different receptor, different signal, different second messenger, different side effect profile. Tesamorelin and ipamorelin are not two versions of the same thing. They are two unrelated keys, and knowing which one you are holding explains almost everything about what you should expect.

Door One: The GHRH Receptor

The first door is the one your own hypothalamus uses.

Growth hormone releasing hormone is a hypothalamic peptide that lands on the GHRH receptor on pituitary somatotroph cells and tells them to build and release growth hormone. The label language on the one FDA approved drug in this class describes it exactly that way: it acts on the somatotroph to stimulate the synthesis and pulsatile release of endogenous GH.

Pulsatile is the operative word. This door does not create a flat, constant GH signal. It amplifies the rhythm you already have. The signal runs through your own pituitary, so it respects your own feedback loops.

Everything in this class is a GHRH analog. Sermorelin, tesamorelin, CJC-1295. They differ in half life and stability, not in the door they open.

Tesamorelin is the one with real human data behind it, because it went through the full approval process rather than staying a compounded peptide. It has been FDA approved since 2010 for reducing excess abdominal fat in adults with HIV associated lipodystrophy, marketed as Egrifta. In the pooled phase III analysis, 2 mg daily reduced visceral adipose tissue by roughly 15 percent against placebo over 26 weeks.

A 2026 meta analysis of the randomized trials found reductions in visceral fat, hepatic fat and waist circumference, plus an increase in lean mass of about 1.4 kg. It also found something most peptide content leaves out: no significant reduction in subcutaneous fat and no significant change in BMI. This compound reorganizes where fat sits. It does not make you lighter.

Door Two: The Ghrelin Receptor

The second door is not a growth hormone pathway at all. It is a hunger pathway that happens to open the same cell.

Ghrelin is the stomach peptide most people know as the hunger hormone. Its receptor, GHS-R1a, is expressed on the same pituitary somatotrophs, and when it fires it releases GH. The receptor was actually discovered backwards: researchers built a synthetic molecule, MK-0677, found the orphan receptor it bound, and only later identified ghrelin as the natural ligand.

Mechanically it is a different machine. The GHRH receptor signals through cAMP. GHS-R1a couples primarily to Gq, activating phospholipase C, inositol trisphosphate and intracellular calcium release. Two separate second messenger systems converging on one cell.

Everything in this class is a ghrelin receptor agonist, whether or not it is a peptide. GHRP-2, GHRP-6, hexarelin, ipamorelin, and the oral non peptide MK-677.

Why Two Doors Beat One

This is the part that explains the stacks.

When GHRH and a ghrelin receptor agonist are given together, the GH response is not additive. It is synergistic. Cell work going back decades shows co treatment producing a potentiated cAMP and GH response beyond what either produces alone.

Two things drive it. The receptors run separate signaling routes, so they are not competing for the same machinery. And the ghrelin pathway also acts on the brake. Somatostatin is the inhibitory signal that shuts GH release down, and ghrelin receptor activity works against it while GHRH pushes on the accelerator.

Push the gas and release the brake at once and you get more than either alone. That is the entire mechanistic logic behind pairing a GHRH analog with a ghrelin agonist, and it is why the pairing is the standard construction rather than a marketing invention.

Not Every Ghrelin Agonist Is the Same Drug

Inside door two the compounds diverge hard, and this is where most of the bad outcomes live.

The early GH releasing peptides were not clean. GHRP-6 and GHRP-2 both raise ACTH and cortisol along with GH. A 1997 study in Peptides found GHRP-2 and hexarelin produced ACTH and cortisol responses comparable in magnitude to CRH itself. GHRP-6 is also the notorious appetite compound, which follows directly from agonizing a hunger receptor.

Ipamorelin was engineered specifically to fix that. The 1998 Novo Nordisk paper that introduced it, titled "Ipamorelin, the first selective growth hormone secretagogue," reported GH release comparable to GHRP-6 with no significant elevation in ACTH or cortisol, and no effect on prolactin, TSH, LH or FSH. That selectivity held at doses more than 200 times the ED50 for GH release.

That is the whole reason ipamorelin displaced the older peptides. Not that it releases more GH. That it releases GH without dragging your stress axis along with it. If someone recommends a ghrelin agonist without being able to tell you its cortisol profile, they are not thinking about it at the level the class requires.

What the Oral Option Actually Costs

MK-677 is the compound most men ask about, because it is oral and long acting. The tradeoff is documented.

The best evidence is Nass and colleagues in the Annals of Internal Medicine in 2008: 65 healthy adults aged 60 to 81, 25 mg daily, two years. It worked. GH and IGF-1 were restored toward young adult levels and fat free mass rose by 1.1 kg against a 0.5 kg loss on placebo.

It also raised fasting blood glucose by roughly 5 mg/dL and reduced insulin sensitivity. Appetite went up, as you would expect from agonizing the hunger receptor. Transient lower limb edema and muscle pain were the other common complaints.

An accompanying editorial in the same issue was blunt about it: a youthful GH and IGF-1 profile and more lean mass, but no demonstrated functional benefit and some worrying adverse effects, specifically increased insulin resistance and decreased glucose tolerance.

MK-677 is not FDA approved for human use. It sits on the World Anti Doping Agency prohibited list, and in 2023 the FDA placed a large number of GH axis peptides including CJC-1295 and ipamorelin into the 503A Category 2 bulk substances list, meaning they need further review before compounding can legally resume.

What to Track

Whichever door is being used, the markers are the same and IGF-1 alone is not the panel.

IGF-1 is the downstream readout and the one everyone checks. Fasting insulin, fasting glucose and HbA1c matter at least as much, because the entire class pushes on insulin sensitivity and the ghrelin side pushes harder. If you are running a ghrelin agonist, morning cortisol is worth having on the panel unless the specific compound has a documented selectivity profile.

This is the same reason a marker panel gets built before any protocol in how we approach it. The compound choice is the easy part. Knowing which numbers it moves against you is the part that decides whether it was worth running.

The Part That Matters

The question is never which peptide is best. It is which door you are opening and what comes through it with the GH.

One door is your own hypothalamic signal, amplified, with the best human trial data in the category and a body composition effect that reorganizes fat rather than reducing it. The other is a hunger receptor that opens the same cell through different machinery, releases more GH, and brings appetite, fluid and glucose consequences that vary enormously depending on which compound in the class you picked.

Anyone who cannot tell you which receptor a compound hits should not be the person telling you to take it.